1-Furan-2-yl-2-oxo-imidazolidin | 19747-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-Furan-2-yl-2-oxo-imidazolidin
• 英文别名: 1-(2'-Furyl)imidazolidin-2-on；1-furan-2-yl-imidazolidin-2-one；1-(Furan-2-yl)imidazolidin-2-one
• CAS: 19747-63-8
• 化学式: C₇H₈N₂O₂
• 分子量: 152.153
• InChiKey: GTWNAFJWIINTDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18
  申请人：Adhaere Pharamaceuticals, Inc.

  公开号：EP3243821A1

  公开（公告）日：2017-11-15

  A pharmaceutical formulation of a β2 integrin agonist including an effective amount of a β2 integrin agonist and a pharmaceutically acceptable carrier. A method of activating β2 integrins by interacting the β2 integrins with a β2 integrin agonist. A method of treating a patient by administering an effective amount of a β2integrin agonist, and activating β2 integrins. A method of treating inflammation by administering a β2 integrin agonist to a patient with inflammation, activating β2 integrins, and reducing inflammation. Methods of treating and/or preventing renal ischemia-reperfusion (I/R) injury, reducing injury in a patient due to insertion of a stent, performing an assay for the identification of small molecule modulators of β2 integrins, detecting a disease in a patient, and improving the general wellness of a patient.

  β2 整合素激动剂的药物制剂，包括有效量的β2 整合素激动剂和药学上可接受的载体。一种通过β2整合素与β2整合素激动剂相互作用来激活β2整合素的方法。一种通过施用有效量的β2整合素激动剂并激活β2整合素来治疗患者的方法。一种治疗炎症的方法，给炎症患者施用β2整合素激动剂，激活β2整合素，减轻炎症。治疗和/或预防肾缺血再灌注（I/R）损伤的方法，减少患者因插入支架而造成的损伤，进行β2整合素小分子调节剂的鉴定试验，检测患者的疾病，改善患者的总体健康状况。
• COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18
  申请人：Adhaere Pharamaceuticals, Inc.

  公开号：EP2591092A1

  公开（公告）日：2013-05-15
• [EN] COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18<br/>[FR] COMPOSÉS ET MÉTHODES POUR RÉGULER L'INTÉGRINE CD11B/CD18
  申请人：ADHAERE PHARAMACEUTICALS INC

  公开号：WO2012005800A1

  公开（公告）日：2012-01-12

  A pharmaceutical formulation of a β2 integrin agonist including an effective amount of a β2 integrin agonist and a pharmaceutically acceptable carrier. A method of activating β2 integrins by interacting the β2 integrins with a β2 integrin agonist. A method of treating a patient by administering an effective amount of a β2 integrin agonist, and activating β2 integrins. A method of treating inflammation by administering a β2 integrin agonist to a patient with inflammation, activating β2 integrins, and reducing inflammation. Methods of treating and/or preventing renal ischemia-reperfusion (l/R) injury, reducing injury in a patient due to insertion of a stent, performing an assay for the identification of small molecule modulators of β2 integrins, detecting a disease in a patient, and improving the general wellness of a patient.